EFHD2 and non-small cell lung carcinoma: A non-steroidal anti-inflammatory drug ibuprofen, which can degrade EFHD2 and thus inhibit EFHD2 expression, could improve the therapeutic response of NSCLC to cisplatin via inhibiting NOX4-ROS-ABCC1 axis (Fan et al., 2020).